Full text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Due to the aggregation‐caused quenching effect and near‐infrared I poor penetration capabilities of common fluorescent molecules, their applications in visualized imaging and photoactivated treatment are limited. Therefore, new near‐infrared II (NIR‐II) molecule (named TST), which had the abilities of aggregation‐induced emission (AIE) and photothermal therapy are synthesized. Moreover, in order to further improve its fluorescent yield and therapeutic effect, camptothecin prodrug (CPT‐S‐PEG) and novel immune checkpoint inhibitor AZD4635 are used to co‐assemble with TST into nanoparticles for drug delivery. On account of the strong interaction of camptothecin and TST, the intramolecular rotation of TST is limited, thereby inhibiting non‐radiation attenuation and promoting fluorescence generation when the nanoparticles are intact. As nanoparticles uptake by cancer cells, redox sensitive CPT‐S‐PEG is degraded and the nanoparticles disintegrate. The released TST enhances non‐radiative attenuation and expedites photothermal conversion because of the removal of the constraint of camptothecin. Furthermore, photothermal therapy induces immunogenic cell death of cancer cells and releases abundant ATP into the tumor microenvironment to recruit immune cells. However, superfluous ATP is converted into immunosuppressive adenosine through the CD39‐CD73‐A2AR pathway. The AZD4635 released by photothermal disintegration of the nanoparticles just blocks this pathway timely, achieving favorable synergistic effect of photothermal therapy, chemotherapy, and immunotherapy.

Details

Title
Dynamic Adjust of Non‐Radiative and Radiative Attenuation of AIE Molecules Reinforces NIR‐II Imaging Mediated Photothermal Therapy and Immunotherapy
Author
Wang, Zhenjie 1 ; Yu, Ling 2 ; Wang, Yuehua 3 ; Wang, Chenlu 4 ; Mu, Qingchun 1 ; Liu, Xiaojing 1 ; Yu, Meng 5 ; Kang‐Nan Wang 6 ; Yao, Guangyu 7 ; Yu, Zhiqiang 5   VIAFID ORCID Logo 

 The People's Hospital of Gaozhou, Maoming, P. R. China 
 Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, P. R. China; AMI Key laboratory of Chinese Medicine in Guangzhou, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, P. R. China 
 Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, P. R. China 
 MOE Key Laboratory for Analytical Science of Food Safety and Biology College of Chemistry, Fuzhou University, Fuzhou, P. R. China 
 Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China 
 Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, P. R. China 
 Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, P. R. China 
Section
Research Articles
Publication year
2022
Publication date
Mar 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
21983844
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2638894781
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.